Glaukos price target raised to $145 from $135 at Wells Fargo

Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $145 from $135 and keeps an Overweight rating on the shares. The firm notes Glaukos reported Q3 sales beating consensus, driven by iDose and OUS MIGS. Management raised sales guidance by $5M at the midpoint, or the magnitude of the beat. Wells sees good momentum for iDose into Q4 and 2025.